Yuan Zhi
Stock Analyst at B. Riley Securities
(0.41)
# 4,082
Out of 4,843 analysts
23
Total ratings
22.73%
Success rate
-27.57%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HYPR Hyperfine | Maintains: Buy | $1.2 → $1 | $0.60 | +65.98% | 2 | May 15, 2025 | |
| MIR Mirion Technologies | Maintains: Buy | $19 → $17 | $19.10 | -10.99% | 2 | Apr 16, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $15 | $4.79 | +213.15% | 1 | Mar 12, 2025 | |
| TNGX Tango Therapeutics | Maintains: Buy | $16 → $8 | $2.22 | +260.36% | 2 | Nov 11, 2024 | |
| AGEN Agenus | Maintains: Buy | $42 → $18 | $3.43 | +424.78% | 2 | Aug 14, 2024 | |
| CYRX Cryoport | Upgrades: Buy | $19 → $15 | $6.04 | +148.55% | 4 | Jul 31, 2024 | |
| CTSO Cytosorbents | Reiterates: Buy | $3 | $0.84 | +257.14% | 1 | May 15, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $12 → $17 | $2.57 | +561.48% | 2 | Apr 9, 2024 | |
| AZTA Azenta | Maintains: Buy | $61 → $79 | $26.70 | +195.88% | 3 | Feb 1, 2024 | |
| ATNM Actinium Pharmaceuticals | Maintains: Buy | $20 → $16 | $1.54 | +938.96% | 4 | Dec 11, 2023 |
Hyperfine
May 15, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.60
Upside: +65.98%
Mirion Technologies
Apr 16, 2025
Maintains: Buy
Price Target: $19 → $17
Current: $19.10
Upside: -10.99%
Radiopharm Theranostics
Mar 12, 2025
Initiates: Buy
Price Target: $15
Current: $4.79
Upside: +213.15%
Tango Therapeutics
Nov 11, 2024
Maintains: Buy
Price Target: $16 → $8
Current: $2.22
Upside: +260.36%
Agenus
Aug 14, 2024
Maintains: Buy
Price Target: $42 → $18
Current: $3.43
Upside: +424.78%
Cryoport
Jul 31, 2024
Upgrades: Buy
Price Target: $19 → $15
Current: $6.04
Upside: +148.55%
Cytosorbents
May 15, 2024
Reiterates: Buy
Price Target: $3
Current: $0.84
Upside: +257.14%
Perspective Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $2.57
Upside: +561.48%
Azenta
Feb 1, 2024
Maintains: Buy
Price Target: $61 → $79
Current: $26.70
Upside: +195.88%
Actinium Pharmaceuticals
Dec 11, 2023
Maintains: Buy
Price Target: $20 → $16
Current: $1.54
Upside: +938.96%